Advaxis Immunotherapy Boosts 12-Month Survival In Cervical Cancer
This article was originally published in Scrip
Advaxis Inc. reported that 38.5% of advanced cervical cancer patients – a group that normally survives for four to seven months on average – survived for at least 12 months after treatment with the company's immunotherapy axalimogene filolisbac (ADXS-HPV) in the first stage of a 67-patient, investigator-initiated, two-stage Phase II clinical trial.
You may also be interested in...
Potentially registrational trial of ADXS-DUAL Listeria-based vaccine with Bristol's PD-1 inhibitor Opdivo in recurrent metastatic cervical cancer will complement Advaxis's adjuvant study of earlier-generation candidate axalimogene filolisbac.
Advaxis is developing – now with help from partner Amgen – a personalized immunotherapy strategy with each patient's cancer vaccine based on their own tumor's specific neoepitopes.
Amgen detailed plans for increasing sales of drugs acquired in its Horizon transaction and outlined growth opportunities in its R&D pipeline during a rare disease showcase.